Dr. Long joined Anokion in 2022 as Chief Medical Officer. She brings 20 years of experience working in the pharmaceutical and biotechnology industry, and a proven track record developing therapies, which include seven successful regulatory approvals over her career. Prior to Anokion, Dr. Long served as Chief Medical Officer at Kaleido Biosciences where she was responsible for the clinical development, clinical operations, medical affairs, and biostatistics functions. Previous to Kaleido, Dr. Long was Interim Chief Medical Officer at Freeline Therapeutics, and prior to her role at Freeline, she served as Head of Clinical Research and Development at Spark Therapeutics, where she oversaw the clinical development of all programs, including gene therapy in Huntington’s and Pompe diseases, as well as Inherited Retinal Disorders. Dr. Long has also previously served in roles of increasing responsibility at uniQure, Aegerion Pharmaceuticals, and Biogen, where she focused on the development and subsequent EU approval of Elocta®. Prior to her executive positions, Dr. Long was a physician scientist at AFG Biosolutions and Brain Chemistry Labs, following 12 years in private internal medicine practice in Johannesburg, South Africa. Dr. Long earned her medical degree from the University of the Witwatersrand in South Africa, and a Ph.D. in medical Biodefense from George Mason University in Fairfax, VA.